•  

Posts Tagged: commercialization agent

Israel’s BioLineRx and Canada’s MaRS Innovation sign framework collaboration agreement

Agreement signed as part of Ontario's life sciences trade mission to Israel TEL AVIV and TORONTO (May 16, 2016) – BioLineRx Ltd. a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed a framework collaboration agreement with MaRS Innovation,  the commercialization agent for 15 of Toronto's top academic institutions. Under the terms of the agreement, BioLineRx intends to review innovative projects and assets of start-up companies originating from MaRS Innovation's members to identify in-licensing, co-development or other ... Read more

SciBX covers Encycle’s partnership with IRICoR, MaRS Innovation and Merck

"The first disclosed grant under Merck & Co. Inc.'s Canadian translational initiative will bolster the ability of macrocycle-based Encycle Therapeutics Inc. to conduct lead optimization of its integrin [a4b7,] inhibitors for inflammatory bowel disease," writes Michael J. Haas in SciBX's feature on the partnership, "Merck Encycles through Canada." The article appears in the publication's December 4, 2014 issue. Read the Encycle press release that prompted this article. The article explores the current grant partnership between Merck, Encycle Therapeutics, MaRS Innovation, the Institute for ... Read more

BioCentury features Vasomune Therapeutics

Vasomune Therapeutics, a MaRS Innovation start-up company from Sunnybrook Health Sciences Centre's Sunnybrook Research Institute, was featured in a BioCentury emerging company profile by Michael J. Haas. The company is currently raising a Series A financing round and recently closed a seed investment with Genome Canada and an unnamed industry partner. MaRS Innovation also contributed a third of the investment, bringing the round's total to $1.5 million. Haas' profile, "Vasomune: Lassoing Tie2," is available behind a paywall on the BioCentury website. Here's a short ... Read more

Simple test could replace surgery to diagnose male infertility

Mount Sinai’s Lunenfeld-Tanenbaum Research Institute has developed a new test that could make a big difference to men facing infertility. A study published in a leading international journal, Science Translational Medicine, details the discovery of a key biomarker that can pinpoint the cause of infertility without the need for invasive surgery. This story was covered by BBC News, ABC News's "PM" with Mark Colvin, CTV News, CBC News, The Toronto Star, Globe and Mail, Ottawa Citizen and the Calgary Herald. About half a million ... Read more

What does MaRS Innovation’s funding extension mean for Toronto’s academic entrepreneurs?

Every six weeks, MaRS Innovation's marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI's activities or one of our start-up companies. You can read the original post on the MaRS blog. Created in 2008, MaRS Innovation (MI) bridges the chasm between the early-stage technologies emerging from its 16 member institutions and successful startup companies and licensable technologies. By offering early-stage funding in tandem with hands-on management, business development, mentorship and intellectual property protection strategy, MI acts as ... Read more

MaRS Innovation awarded $15 million to further commercialize world-leading Canadian innovations

Networks of Centres of Excellence recognizes strength of partnership between MI and its 16 member institutions TORONTO, February 5, 2013 — How do you make sure the brilliant ideas emerging from Toronto’s academic research community get the best possible chance to succeed? MaRS Innovation (MI), created in 2008, bridges the chasm between these early-stage technologies and successful start-up companies and licensable technologies. By offering early-stage funding in tandem with hands-on management, mentorship and IP strategy protection, MI acts as a commercialization agent for ... Read more